Related Experiment Video

Updated: Jun 14, 2026

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

17.7K

Targeting EBV is a viable therapeutic strategy in MS: No

Niels Hellings1

  • 1Neuro-Immune Connections and Repair (NIC&R) Lab, Department of Immunology and Infection, Biomedical Research Institute, Hasselt University, Diepenbeek, Belgium; University MS Center (UMSC), Diepenbeek-Pelt, Belgium.

Multiple Sclerosis (Houndmills, Basingstoke, England)
|January 14, 2026
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.7K
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.1K

Related Experiment Videos

Last Updated: Jun 14, 2026

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

17.7K
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.7K
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Articles linked to this work by shared authors, journal, and citation graph.

Cytomegalovirus Drives the Development of Cytotoxic CD4+ T Cells in Patients With Multiple Sclerosis.

Neurology(R) neuroimmunology & neuroinflammation·2026

The human TIMP-1 unbound structure provides a platform for fragment screening.

Acta crystallographica. Section D, Structural biology·2026

Peripheral Immune Remodeling After Spinal Cord Injury: Marked by Expansion of CD38+, CTLA-4+, and PD-1+ T and NK Cells.

Neurology(R) neuroimmunology & neuroinflammation·2026

Mucosal Vaccination Against SARS-CoV-2 Using Human Probiotic Bacillus subtilis Spores as an Adjuvant Induces Potent Systemic and Mucosal Immunity.

Vaccines·2025

A new player in the game: identification of C1ql1 as a novel factor driving OPC differentiation.

The FEBS journal·2024

The Impact of Sample Storage on Blood Methylation: Towards Assessing Myelin Gene Methylation as a Biomarker for Progressive Multiple Sclerosis.

International journal of molecular sciences·2024

Subvoxel quantitative susceptibility mapping reveals distinct susceptibility patterns and clinical associations of juxtacortical paramagnetic rims in multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026

Effectiveness of the recombinant zoster vaccine in adult patients with multiple sclerosis: A claims-based retrospective cohort study in the United States.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026

Gynecologic complications of disease-modifying therapy in women with multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026

Emergency department use before multiple sclerosis: Presenting complaints and discharge diagnoses.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026

Colorectal cancer screening in individuals with multiple sclerosis: A mixed-methods study.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026

Increased exertion variability is linked to disruptions in effort assessment in multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026

PET RANO 1.0 vs. RANO 2.0 criteria for trial eligibility in IDH-wildtype glioblastoma: a retrospective, comparative study.

Neuro-oncology·2026

Precision Medicine in patients with rare forms of genetic obesity: Necessity for coordinated and structured care.

The Journal of clinical endocrinology and metabolism·2026

Advances in Formulation and Technological Strategies for Montelukast Pulmonary Delivery.

ACS omega·2026

Feasibility of Polylactic Acid-Polycaprolactone-Blended Microspheres in Transarterial Embolization Therapy.

ACS omega·2026

Exosomes in brain diseases: Mechanisms, advances, and perspectives.

Bioactive materials·2026

Quantification of Ocular Gene Therapy-Related Inflammation Using the VRMACS Grading System.

Ophthalmology science·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us